(A) The distribution of mutations within the 3D structure of the TP53 protein. by Ashraf Attia Mahmoud (21262201)

Subjects:

The result of the secondary structure prediction of native and six mutant proteins of TP35 protein using the SOPMA server. by Ashraf Attia Mahmoud (21262201)

Subjects:

Graph illustrating the distribution of mutations across 20 genes. by Ashraf Attia Mahmoud (21262201)

Subjects:

Molecular dynamics simulation results for Apo-TP53 (red), wild-typeTP53. by Ashraf Attia Mahmoud (21262201)

Subjects:

Effect of mutations on protein stability predicted by I-MUTANT 2.0, MUpro and CUPSAT. by Ashraf Attia Mahmoud (21262201)

Subjects:

P53 mutant docking results (HDOCK and pyDOCK servers). by Ashraf Attia Mahmoud (21262201)

Subjects:

Oncogenic Classification of TP53 missense mutations. by Ashraf Attia Mahmoud (21262201)

Subjects:

Computational analysis of missense mutations using PhD-SNP, PANTHER and, SNPs&GO. by Ashraf Attia Mahmoud (21262201)

Subjects:

Redocking results showing the interaction between the TP53 protein (white ribbon) and its DNA dodecamer ligand (magenta and blue) from PDB ID: 2AC0, highlighting the binding confor... by Ashraf Attia Mahmoud (21262201)

Subjects:

Result of the phenotypic analysis. by Ashraf Attia Mahmoud (21262201)

Subjects:

Oncogenic nature of mutations predicted using CScape and CScape-somatic. by Ashraf Attia Mahmoud (21262201)

Subjects:

(A) Pie chart showing the distribution of mutation types identified within the TP53 gene. by Ashraf Attia Mahmoud (21262201)

Subjects:

Structural clashes in TP53 mutants: (A) G266E mutation causes steric clashes with PHE109 and LEU257, destabilizing the structure. by Ashraf Attia Mahmoud (21262201)

Subjects:

(A) TP53 expression levels are elevated in TP53-mutant and nonmutant HNSC samples compared to normal tissues. by Ashraf Attia Mahmoud (21262201)

Subjects:

Type of Mutations. by Ashraf Attia Mahmoud (21262201)

Subjects:

Supplementary Material for: Adjunctive active vitamin D (AVD) decreases kidney function during treatment of secondary hyperparathyroidism (SHPT) with extended-release calcifediol (... by figshare admin karger (2628495)

Fig 5 - by Kirralise J. Hansford (20670869)

Subjects:

Growth of certain cancer cell lines requires IRE1 but not its enzymatic activity. by Iratxe Zuazo-Gaztelu (21071939)

Subjects:

IRE1 depletion downregulates multiple cell cycle proteins in synchronized cells. by Iratxe Zuazo-Gaztelu (21071939)

Subjects:

IRE1 depletion induces cell cycle arrest independently of apoptosis. by Iratxe Zuazo-Gaztelu (21071939)

Subjects: